89 results about "Sacroiliitis" patented technology

The invention discloses a deep learning algorithm-based spinal MRI precise synthesis CT image processing system and method for central axis type spinal arthritis, and the system comprises a data obtaining unit which is used for obtaining a three-dimensional T1 weighted multi-gradient echo sequence, a T2 weighted sequence and a water-fat separation sequence which are obtained through the magnetic resonance imaging of the spinal column of a target user; the spatial registration unit is used for inputting the multi-sequence data into a deformable registration network so as to carry out spatial registration on the multi-modal features; the feature processing unit is used for carrying out feature fusion on the registered multi-modal features and carrying out double-domain splitting based on an anatomical attention gating mechanism to obtain skeleton features and soft tissue features; and the image fusion unit is used for synthesizing a synthesized CT image with an HU value corresponding to the spine of the target user based on the skeleton features and the soft tissue features, so that radiation-free high-precision CT image acquisition is realized, the diagnosis grading requirement on the axis type spine joint in the spine can be met, and the influence of radiation on the target user can be reduced.

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

A sacroiliac (SI) joint implant assembly addresses SI joint dysfunction and degenerative sacroiliitis. The assembly includes a first implant body, a second implant body, and a piezoelectric layer positioned between them. The piezoelectric layer generates electrical charges when subjected to mechanical stress, stimulating bone growth and enhancing stability of the SI joint after surgery. The implant bodies may feature non-planar surfaces to distribute compressive and shear forces unevenly across the piezoelectric layer. The assembly can be secured using fasteners such as screws, pins, or brackets, and may include porous or fenestrated bodies made from materials like titanium or polymers. Some implant assemblies are designed for minimally invasive surgical procedures, with configurations that allow for precise placement using guide wires and imaging techniques. The assembly aims to stabilize the SI joint and promote bone fusion, leveraging the piezoelectric effect to improve the overall efficacy of the fusion procedure.

The invention relates to the technical field of medical image auxiliary diagnosis, and provides an intervertebral joint osteoarthritis image feature evaluation method based on deep learning, which can synchronously identify five types of FJOA image features such as joint space stenosis, osteophyte, hypertrophy, subchondral bone erosion and subchondral cyst, and improves the comprehensiveness and efficiency of evaluation. The nnU-Net model is adopted to perform high-precision segmentation on an intervertebral joint region, so that the positioning precision is effectively improved; by introducing a shared feature extraction network based on ResNet-18 and five parallel classification sub-networks, joint modeling of multi-scale semantic information is realized, and the recognition accuracy and generalization ability of the model are improved; according to the method, a Grad-CAM technology is combined to generate an activation thermodynamic diagram, a model interpretation basis is superposed to an original image, visual display of an evaluation result is realized, interpretability and clinical applicability of the model are enhanced, and FJOA image features in axial lumbar vertebra CT images from two central data sets can be quantitatively evaluated so as to comprehensively quantify individual FJOA image features.

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis or psoriatic arthritis, utilizing anti-IL-23A antibodies.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

The present invention provides an aqueous pharmaceutical product comprising an anti-IL-17A antibody, and a use of the aqueous pharmaceutical product in the preparation of a drug for treating axial spondyloarthritis.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein (I) can inhibit TNFR1 and is expected to be useful as a therapeutic agent for treating, for example, inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa.The present disclosure also provides a pharmaceutical composition comprising the compound disclosed herein or a pharmaceutically acceptable salt thereof.The present disclosure also relates to a method of using the compound or a pharmaceutically acceptable salt thereof in the treatment and prevention of inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa, as well as a method of preparing a medicament for this purpose. [Formula 1] TIFF0007746628000195.tif82167

The invention belongs to the field of bone nutrition powder, and particularly relates to bone nutrition powder for assisting in relieving arthritis pain and a preparation process. In the preparation, the herba eupatorii extract and the kelp extract are matched to effectively improve the arthritis pain relieving effect of the preparation, and the lophatherum gracile, the raspberry, the motherwort and the purslane are adopted to further improve the arthritis pain relieving effect of the fermented product through the processes of fermentation and the like; the preparation is applied to preparation of the bone nutrition powder, and the bone nutrition powder for assisting in relieving arthritis pain is prepared from the bone nutrition powder, protein, fat, water-soluble dietary fibers, vitamins, mineral elements and chondroitin sulfate. The obtained bone nutrition powder can effectively provide nutrition, also has an excellent health care effect, assists in relieving arthritis pain, and is excellent in performance and relatively good in application prospect.

The invention belongs to the technical field of biological medicine, and particularly relates to a new Spp1 + Carmil1 + and Spp1 + Cav1 + macrophage subgroup, a screening method and application in diagnosis and treatment of rheumatoid arthritis (RA). Aiming at the function limitation of a traditional M1 / M2 classification model, the invention proves the following new subgroup pathological interaction mechanism: osteoclast (ACP5 +) specifically releases TNFSF11 (RANKL), and is co-localized with Spp1 + Carmil1 + and Spp1 + Cav1 + subgroup space; the Spp1 + Carmil1 + subgroup secretes IL-18, and space interaction exists between the Spp1 + Carmil1 + subgroup and Treg (Foxp3 +) and Th17 (Il17a +) cells. The invention provides a novel cell marker and a targeted treatment strategy for accurate diagnosis and treatment of RA.

The present disclosure relates to inhibitors of miR-574-5p (SEQ ID NO: 1) for use in intra-articular treatment of a disease selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, gout, juvenile arthritis, systemic lupus erythematosus (SLE), Sjögren's syndrome and osteoporosis.

A method for modeling temporomandibular joint osteoarthritis, 6-week-old rats are selected, the rats are confirmed to have entered an anesthetized state before surgery, the rat's mandibular incisors are first checked and confirmed to be normal, the first arm of the device is sleeved on one side of the mandibular incisor, and the palatal side of the maxillary incisor is made to touch the slope surface of the second arm of the device, the device is checked and confirmed to not affect the rat's mandibular movement and occlusion, not significantly raise the bite, have no early contact, and the upper and lower jaw relationship is relatively stable; the device and the mandibular incisor sleeved with the device are fixed; then the rat is put back into the cage, and soft food or powdered feed is given after waking up; the device is removed after being fed for 8 weeks or more. It is verified that the condylar process of the rat changes significantly, the overall condylar process is significantly reduced, the subchondral bone is destroyed, and the expression of the cartilage matrix is also reduced. Thus, a TMJOA rat model exhibiting mandibular retrusion is formed.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

This disclosure provides substituted 6-imidazopyridazine compounds for the modulation of IL-17A and pharmaceutical compositions thereof. These compounds are useful in the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis, or ankylosing spondylitis.

The disclosure herein provides substituted 6-imidazopyridazine compounds, and pharmaceutical compositions thereof, for use in the modulation of IL-17A. These compounds are useful in the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis or ankylosing spondylitis.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, utilizing anti-IL-23A antibodies.

This application discloses a medical information data processing system and method for spondyloarthritis based on an intelligent agent learning model. The system includes: a pre-consultation intelligent agent module for generating an initial medical record in response to the patient's pre-consultation interaction data; a medical data processing intelligent agent module for acquiring the initial medical record and the patient's heterogeneous medical test data, and extracting medical entity information data related to spondyloarthritis from the initial medical record and heterogeneous medical test data using a BERT-BiLSTM-CRF hybrid model, and determining the entity information links formed by the medical entity information data using an EMR-Graph entity relationship graph model; and a medical reasoning intelligent agent module for performing reasoning analysis on the entity information links using an LSTM-TPP model to obtain the initial reasoning probability between the patient and spondyloarthritis. This module can fully consider the link relationship between medical entity information related to spondyloarthritis during the disease probability reasoning process, thereby effectively improving the accuracy of disease probability reasoning.

The invention discloses a spinal arthritis medical information data processing system and method based on an agent learning model, and the system comprises a pre-inquiry agent module which is used for responding to pre-inquiry interaction data of a patient to generate an initial medical record; the medical data processing agent module is used for acquiring the initial medical record and the heterogeneous medical detection data of the patient, and extracting medical entity information data related to the spinal arthritis from the initial medical record and the heterogeneous medical detection data by utilizing a BERT-BiLSTM-CRF hybrid model; determining an entity information link formed by the medical entity information data by using an EMR-Graph entity relation graph model; the medical reasoning agent module is used for performing reasoning analysis on an entity information link by adopting an LSTM-TPP model to obtain an initial reasoning probability between a patient and the spondyloarthritis, and can fully consider a link relationship with medical entity information related to the spondyloarthritis in a disease probabilistic reasoning process; therefore, the accuracy of disease probabilistic reasoning is effectively improved.

To provide an etanercept pharmaceutical composition, a method for producing the same, and a method for treating a patient having rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or psoriasis.SOLUTION: A pharmaceutical composition comprising 75mM to 150mM NaCl, 5mM to 100mM arginine, 0.5% to 2% (w / v) sucrose, and 40mg to 100mg / mL etanercept, wherein the composition comprises 2. less than 0mM total additional buffer, and wherein the pH of the composition is between 6.1 and 6.5.SELECTED DRAWING: Figure 1

The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

The invention belongs to the technical field of biological medicines, and particularly relates to a drug-loaded nano-micelle as well as a preparation method and application thereof. According to the invention, bromoalkanes with different chain lengths are introduced to a leonurine phenolic hydroxyl group by adopting a total synthesis method to prepare a leonurine derivative, and the drug-loaded nano-micelle is prepared by applying triptolide (TP) and the leonurine derivative. The embodiment of the invention verifies that the drug-loaded nano-micelle can reduce in-vivo and in-vitro toxicity caused by triptolide and improve the treatment effect on a mouse arthritis model induced by type II collagen. The novel triptolide compatible medicine prepared by the invention is small in toxic and side effects and has a good curative effect on rheumatoid arthritis.

The invention discloses a central axis type spinal arthritis sacroiliac joint MRI synthesis CT image processing system and method based on a deep learning algorithm, and the system comprises a data obtaining unit which is used for obtaining magnetic resonance sequence data obtained through the magnetic resonance imaging of a sacroiliac joint of a target user; the deep learning model unit is used for inputting the magnetic resonance sequence data into a deep learning algorithm model trained by federal learning to obtain bone cortex features and soft tissue features of sacroiliac joints; the image synthesis unit is used for synthesizing a synthesized CT image corresponding to the sacroiliac joint of the target user based on the bone cortex features and the soft tissue features, non-radiation high-precision CT image acquisition is achieved, the diagnosis requirement for the axial spine joint in the sacroiliac joint can be met, and the influence of radiation on the target user can be reduced.

The invention provides certain difluorotetrahydropyran-imidazotriazine compounds of formula I as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula I to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

The application relates to the technical field of animal models, and discloses a construction method and application of an ectopic ossification arthritis animal model. 91‑115 After being mixed and emulsified with chicken type II collagen as an antigen, animals are immunized to obtain the animal model, which is referred to as a C2V7 model. The arthritis model constructed by the application has high success rate, short time consumption and easily-obtained modeling materials. The model can simulate the onset process of arthritis with obvious ectopic ossification characteristics such as ankylosing spondylitis, enthesial-related arthritis and psoriatic arthritis, objectively reflects the pathological process and pathological characteristics of ectopic ossification arthritis, and provides a new research platform for related research.

The present invention relates to montelukast for use in the treatment of erosive hand osteoarthritis. According to this use, montelukast can be administered either orally or topically, in the form of any suitable pharmaceutical composition. Patients suffering from erosive hand osteoarthritis treated with montelukast showed improvement in clinical symptoms and in radiological parameters, and also reported pain relief and hand functionality improvement.

The present disclosure relates to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, such as AIN457 (secukinumab), and processes for manufacturing these pharmaceutical products and compositions. The present disclosure also relates to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit with instructions for use) for the treatment of various IL-17-mediated diseases (e.g., autoimmune diseases, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

This application discloses a system and method for processing precise synthetic CT images of the spine based on deep learning algorithms for axial spondyloarthritis. The system includes: a data acquisition unit for acquiring three-dimensional T1-weighted multi-gradient echo sequences, T2-weighted sequences, and water-lipid separation sequences obtained from magnetic resonance imaging of the target user's spine; a spatial registration unit for inputting multi-sequence data into a deformable registration network to perform spatial registration of multimodal features; a feature processing unit for fusing the registered multimodal features and performing dual-domain splitting based on an anatomical attention gating mechanism to obtain skeletal features and soft tissue features; and an image fusion unit for synthesizing synthetic CT images with HU values ​​corresponding to the target user's spine based on skeletal features and soft tissue features, achieving radiation-free, high-precision CT image acquisition, which can meet the diagnostic and grading requirements of axial spondyloarthritis while reducing the impact of radiation on the target user.